Results: A total of 26 studies including 5,939 patients were enrolled in the present meta-analysis. Tumor-derived SPARC overexpression was significantly related with poor overall survival (hazard ratio: 1.478; 95% CI: 1.143-1.910; p=0.003), and a similar tendency was also observed in disease-free survival (hazard ratio: 1.476; 95% CI: 0. 993-2.195; p=0.054). However, the hazard ratios for overall survival and disease-free survival did not present a statistical trend in stromal SPARC overexpression. Tumor type subgroup analysis revealed marked heterogeneity among outcomes. In pancreatic cancer, SPARC overexpression in the stroma was significantly associated with poorer overall survival and disease-free survival. In colorectal cancer, SPARC overexpression in the stroma was associated with better disease-free survival.
T he tumor microenvironment theory states that the survival and development of tumors are dependent on the whole tumor environment. 1 Based on the modern cancer model, cancer-associated fibroblasts (CAFs), the predominant cellular components surrounding cancer cells, serve a crucial role in tumor proliferation, metastasis, drug resistance and other biological phenotypes. 2 Secreted protein acidic and rich in cysteine (SPARC), mainly produced by fibroblasts, chondrocytes and osteoblasts, is a member of the matricellular family of proteins. 3 Secreted protein acidic and rich in cysteine modulates interactions between cells and the extracellular matrix, participating in normal tissue remodeling and wound repair. 4, 5 Nowadays, emerging evidence has shown the participation of SPARC in various cancer progression. Though numerous studies have revealed that SPARC was expressed in different types of cancers, the exact function of SPARC is controversial. Some reports have shown that SPARC may contribute to cell adhesion, angiogenesis and proliferation, and the overexpression of SPARC was associated with tumor metastasis and poor prognosis in biliary tract, pancreatic, breast and non-small cell lung cancers. [6] [7] [8] [9] [10] However, other studies have reported that SPARC served an inhibitory role in angiogenesis and tumor formation, resulting in favorable prognosis in gastric cancer and diffuse large B-cell lymphoma. 11, 12 Given that the different localization of SPARC also had different outcomes, Nakashima et al 7 demonstrated that stromal SPARC expression was associated with several clinicopathological parameters and was indicative of a poor prognosis, while the tumoral SPARC expression within homologous niches failed to draw a significant conclusion. Therefore, the prognostic value of SPARC in the tumor microenvironment is still unclear, and the heterogeneity of the mechanisms among different solid tumors and different cellular locations also requires elucidation. Thus, in order to further clarify the role of SPARC in the malignant solid tumor microenvironment, the present study performed a meta-analysis to evaluate the expression level of SPARC in 9 different types of solid tumors and the expression differences between cancer and stromal cells, especially
CAFs. In addition, the present study systematically analyzed the heterogeneous functions of SPARC in different tumor micro-environments with the purpose of determining its clinical significance.
Methods. The review was reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.
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Search strategy. Database and manual searches were undertaken to identify relevant articles written in the English language. A systematic search was conducted in May 2019 following PRISMA ( Figure 1A ) in 5 databases (PubMed, CINAHL, Cochrane, Web of Science and Embase). The search terms were as follows: ("osteonectin" OR "SPARC glycoprotein" OR "BM-40" OR "basement membrane tumor protein" OR "BM 40 protein" OR "SPARC" OR "secreted protein acidic and rich in cysteine") AND ("neoplasm" OR "neoplasia" OR "tumor" OR "tumour" OR "cancer" OR "carcinoma" OR "malignancy" OR "malignant" OR "cancerous" OR "carcinomatous" OR "cancroid"). The reference lists of any relevant systematic reviews found via the search were screened to identify potentially eligible additional primary studies. Appendices of the reference lists of the included studies were also undertaken.
Study selection. Articles were included if they were retrospective studies that focused on the clinical implications of SPARC expression on overall survival (OS) and disease-free survival (DFS). Additionally, the following criteria were also fulfilled: i) SPARC expression was evaluated by immunohistochemistry (IHC); ii) the location of SPARC was precisely described and the analysis was performed in cancer and stroma cells independently; and iii) targeted outcome data were either reported or were able to be estimated from the relevant published data. Articles were excluded if they fulfilled any of the following criteria: i) If they were literature reviews, abstracts, case reports or letters; ii) if enrolled patients received neoadjuvant treatment, such as chemotherapy or radiotherapy prior to surgery; iii) if studies were performed in vitro or without clinical data available for the present analysis; and iv) if studies were repeated or duplicated. Two authors conducted the search and independently reviewed the titles and abstracts according to the inclusion criteria. Two authors determined the selection of articles included in the sample. Disagreements about inclusion decisions were resolved by consensus and consultation with a third reviewer.
Data extraction. Two authors independently extracted the data from all of included papers into Excel spreadsheets. Discrepancies in the data were resolved through consensus. The following information was collected from each study: first author, year of publication, country of origin, tumor type, number of enrolled patients, SPARC location, SPARC positive rate, SPARC antibody, cut-off value for overexpression, tumor size, invasion depth, lymph node metastasis, degree of differentiation, clinical stage, hazard ratios (HRs) with their 95% confidence intervals (95% CIs) for OS and DFS. Methods described by Tierney et al 14 were
used to estimate the HRs and 95% CIs if the survival data were not reported directly. Additionally, survival rates were extracted using the Engauge Digitizer for Mac version 10.11 based on Kaplan-Meier curves for the subsequent calculation. Quality appraisal. Two reviewers independently evaluated the 26 articles using the Newcastle-Ottawa Scale (NOS), which has 8 items. 15 This scale has been developed as the main evaluation method for non- randomized control studies and the scale for cohort studies was applied in the present analysis. Statistical analysis. The meta-analysis was performed using STATA for Mac version 14.1 (StataCorp LP, College Station, TX, USA). The foremost outcomes for OS/DFS were measured based on the HR with 95% CI. The heterogeneity of these studies was assessed by Q-test and I 2 -test. A random-effects model was applied when heterogeneity existed among studies (p<0.05 or I 2 >50%), otherwise a fixed-effects model was used.
To explore the source of the heterogeneity of studies, subgroup analysis and meta regression were performed. The publication bias was evaluated by funnel plot and Egger's linear regression test, and p<0.05 indicated a significant publication bias among the enrolled studies. The stability of the results was confirmed by sensitivity analysis. A p<0.05 was considered to indicate statistically significant difference.
Results. Search results. The process of how studies were selected is presented in Figure 1A . The initial search identified 3,872 articles. Once the duplicates were removed and 2,066 titles and abstracts had been screened, 99 articles were identified for full-text review. Finally, 26 articles met the eligibility criteria. Studies were excluded due to the following reasons: i) No outcomes were available; ii) could not extract the raw data; iii) failure to distinguish tumoral expression from stromal expression; and iv) different evaluation methods. Study characteristics. The basic characteristics of the enrolled studies were presented in Table 1 . Briefly, the number of patients in each study ranged from 36 to 1,093, and a total of 5,939 patients from 11 countries were included in the present meta-analysis. The studies focused on solid tumors, including gastric cancer, 11, [16] [17] [18] esophageal squamous cell carcinoma, 19, 20 pancreatic cancer, 8, [21] [22] [23] [24] [25] lung cancer, 10, 26, 27 breast cancer, 4, 9, 28 colorectal cancer, [29] [30] [31] [32] diffuse large B-cell lymphoma, 12, 33 biliary tract cancer, 7 and nasopharyngeal carcinoma. 34 The positive rates of SPARC varied among the 9 solid tumors, and in the same tumor type, the positive rates of SPARC expressed in cancer and stromal cells were also different ( Figure 1B) . The laboratory information and cut-off values for SPARC overexpression were presented in Appendix 1. The judgement of the cut-off varied depending on the methods they used, among which one study did not mention the evaluation of the cut-off value. 4 For the convenience of the meta-analysis, some polytomous variables within studies were transformed into binary variables to calculate the OR or HR. Every eligible study gained a NOS score >6, indicating that all of the enrolled studies reached the high levels of methodological quality for meta-analysis (Appendix 2).
Overall survival. Figure  2B ). And in respiratory tract tumors, SPARC was also negatively associated with OS (HR: 1.774; 95% CI: 1.465-2.149; p<0.001; Figure 2B ). No publication bias was observed among the enrolled studies (PEgger=0.067).
As for stromal analysis, 15 studies with 3,244 patients were included and the random-effects model was applied (x 2 =69.63, p<0.001, I 2 =79.9%). However, no significant relation was observed (HR: 1.261; 95% CI: 0.908-1.751; p=0.166; Figure 3A) . Additionally, the following subgroup analysis for precise tumor types revealed that, in pancreatic cancer, SPARC overexpression in the stroma was significantly associated with poorer OS (HR: 1.745; 95% CI: 1.164-2.616; p=0.007; Figure 3B ). The Egger's tests demonstrated the publication bias that existed among the enrolled studies (PEgger=0.009).
Disease-free survival. Data on the DFS of patients were reported by 5 studies in regard to cancer cells and 4 studies on stromal cells. The random-effects models were used for the two groups ( Figure 4A) .
No statistically significant relation between SPARC overexpression in stromal cells and DFS was observed (HR: 0.903, 95% CI: 0.465-1.754; p=0.762; Figure 4B ). However, subsequent analysis of the tumor type subgroups revealed that in pancreatic cancer, SPARC overexpression in stromal cells was associated with poorer DFS, and in colorectal cancer, stroma-derived SPARC overexpression was associated with better DFS (pancreatic HR: 1.577, 95% CI: 1.211-2.055; p=0.001; colorectal HR: 0.504, 95% CI: 0.350-0.727; p<0.001). No publication bias was observed among the enrolled studies (cancer PEgger=0.201; stroma PEgger=0.309).
Meta regression. In order to influence the covariates, such as the design of the enrolled studies and clinicopathological characteristics, towards the outcome OS, meta regression was perform in the present analysis. Year of publication, country, HR obtainment, tumor type and sample size were induced into the regression models. As a result, none of the covariates accounted for the sources of the heterogeneity in cancer cell group and stromal cell group (Appendix 3).
Funnel plot. The publication bias was evaluated by funnel plot when calculating all effect sizes (Appendix 4A-4D). As a consequence, combined with the results of the Egger's linear regression test, the publication bias was observed when analyzing the association between SPARC overexpression in stromal cells and OS. And no significant publication bias was observed among other analysis.
Sensitivity analysis. In order to investigate the influence of individual study on the overall metaanalysis summary estimate, sensitivity analysis was also performed among the evaluated outcomes with high heterogeneity using STATA 14.1. Outcomes including OS and DFS were assessed. In addition, no significant changes were detected between the previous and new effect sizes when one single study was deleted every time, which indicated that the results were relatively stable during the meta-analysis (Appendix 4E-4H).
Discussion. In the present meta-analysis, the HRs and 95% CIs were calculated for OS/DFS among enrolled studies to summarize the association between SPARC expression and long-term survival. However, the results changed with the translocation of SPARC expression. SPARC overexpression in cancer cells was significantly related with poor OS. In view of the heterogeneity, subgroup analysis was performed by stratifying the pooled data according to tumor types. In gastrointestinal and respiratory tract tumors, cancer-derived SPARC overexpression was indicative of a poorer OS. Similar results were also observed in the analysis for DFS, though the HR in the cancer cell group was not statistically significant. Additionally, the differences of sample sizes among the studies might be the source of the heterogeneity. For stromal analysis, the HR for OS and DFS did not present a statistical tendency in respect to SPARC overexpression. However, in pancreatic cancer, SPARC overexpression in the stroma was significantly associated with poor OS as well as DFS, and in colorectal cancer, SPARC overexpression was associated with better DFS, which indicated a marked tumor type heterogeneity in stroma-derived DFS in the cancer cell group. B) DFS in the stromal cell group. HR -heart rate SPARC. Although there was possible publication bias in the enrolled retrospective studies when analysis for OS in the stromal cell group was performed, the results were strengthened by the large sample size, and the source of the heterogeneity due to tumor types was also determined. Additionally, the sensitivity analysis also indicated a stable result. For the majority of solid tumors, SPARC overexpression in cancer cells may be an indicator for poor long-term survival, but the role in the stroma largely depends on the type of tumors. Overall survival and DFS are effective indexes to assess the benefits or risks of the intervention in patients with cancer. Previous studies have reported various signaling pathways that SPARC may be involved in to affect the oncological outcomes, such as Urokinase-type plasminogen activator (uPA)-uPA receptor, phosphoinositide 3-kinase/protein kinase B, and mitogen activated protein kinase, contributing differently to patients' long-term survival. 35, 36 However, signaling pathways SPARC involved in among different tumor microenvironments may weighted diversely and lead to different outcomes, which partially accounts for the heterogeneity of SPARC in pancreatic cancer and colorectal cancer. Given its association with albumin binding, SPARC also participates in the response to adjuvant chemotherapy. Nab-paclitaxel, a first line drug for various types of cancers, can be trapped in the tumor stroma with the help of SPARC, and the stromal depletion effect enables cancer cells to have tumor-tumor and tumor-vessel communications. 37, 38 The interference in the therapeutic response may also make a difference in the survival rates.
The abilities of tumor migration and invasion largely depend on the strong viability of tumor cells and their frequent crosstalk with the microenvironment. One of the most important mechanisms is epithelial-mesenchymal transition (EMT). Zhang et al 39 demonstrated that in cancer metastasis mouse models, mice injected with SPARC-overexpressing gastric cancer cells had much fewer lung metastases than those administered the control cell injection. Previous studies have revealed that the inhibition of matrix metalloproteinase (MMP)-7, MMP-9, N-cadherin, Sp1 and extracellular signal-regulated kinase 1/2 by SPARC may account for this phenomenon. Nevertheless, some studies have also reported that SPARC overexpression could interfere with collagen incorporation into basement membranes, which potentially destroyed the barrier function of basement membranes and facilitated invasive cells to breach the natural defense in situ. 40 Thus, the roles of SPARC in the clinicopathological characteristics varied and we hypothesized that the effects of SPARC on tumor progression were systematically modulated and specifically weighted within different microenvironments.
During all events, divergent roles of SPARC in different types of tumor and different expression locations require further investigation. Additionally, the receptors and direct pathways that SPARC was involved in have not been discovered. Future studies should focus more on tracing the diverse paths of SPARC in tumor parenchyma as well as the stroma, and interactions within different tumor microenvironments.
The present study has some strengths and limitations. We comprehensively overviewed the expression level of SPARC in 9 types of solid tumors and the expression differences between cancer and stromal cells were evaluated in regard to clinicopathological characteristics and long-term survival. In order to minimize the heterogeneity as much as possible, the present study rigorously restricted the inclusion and exclusion criteria. In order to investigate the exact behaviors of SPARC from different cellular origins, only studies using the IHC method, which clearly located the expression positions in tumor tissues, were enrolled. In addition, studies with neoadjuvant therapy were excluded; some studies have reported that the expression level of SPARC could be altered when patients received chemotherapy. 16 Additionally, sensitivity analysis was performed for all the results with high heterogeneity to verify the stability of the conclusions drawn.
Study limitations. Firstly, the studies mainly focused on pancreatic and colorectal cancer; other types of tumors such as nasopharyngeal carcinoma require more studies and larger sample sizes to support conclusions. Secondly, the enrolled studies were mainly retrospective, but not randomized controlled trials; although the present study tried to control confounding factors, the heterogeneity and publication bias inevitably existed among the eligible studies. The SPARC antibodies they applied, the method to define cut-off values and the ethnicity investigated may all be factors that influenced the homogeneity of the outcomes. Thirdly, some data on HRs were not provided in the original articles and thus, the present study estimated them from Kaplan-Meier curves with the help of an Engauge Digitizer, which led to inaccuracy to some degrees. Finally, only English articles were included, which may have caused the loss of some valuable studies published in other languages.
In conclusion, for the majority of solid tumors, SPARC overexpression in cancer cells may be an indicator of poor long-term survival, but their role in the stroma largely depends on tumor type. In pancreatic cancer, SPARC overexpression in the stroma is significantly associated with poor OS and DFS, and in colorectal cancer, stroma-derived SPARC overexpression is associated with a better DFS, which is indicative of the heterogeneity of SPARC in different tumor types and different expression locations. Secreted protein acidic and rich in cysteine may be a potential biomarker for solid tumor prognosis. More studies on certain tumors such as diffuse large B-cell lymphoma should be performed in the future to provide a comprehensive understanding of SPARC, and the detailed mechanisms also need further study to explain the heterogeneity in different tumor microenvironment.
